Photo Credit: Prostock-Studio
Three different dual antihypertensive therapies demonstrated their safety and effectiveness among patients from India with uncontrolled blood pressure (BP) in the randomized-controlled TOPSPIN trial. All single-pill therapies were safe and associated with similar rates of hypertension control. These findings are reassuring regarding the administration of guideline-directed antihypertensive therapies in a large part of the global population.
The multicenter, single-blind TOPSPIN trial compared three dual therapies for hypertension control among patients from India with uncontrolled BP (n=1,981)1,2. The three dual therapies were amlodipine plus perindopril, amlodipine plus indapamide, and perindopril plus indapamide. The primary outcome was the reduction in 24-hour ambulatory BP at 6 months. Patients were eligible to participate if they had a ‘sitting office’ systolic BP of 140–159 and were using one antihypertensive agent, or if they had a ‘sitting office’ systolic BP of 150–179 and were untreated.
“There was a mean reduction of 14 mmHg in ambulatory systolic BP across the three groups at 6 months,” said Prof. Dorairaj Prabhakaran, MD, from the Center for Chronic Disease Control, in India1. “There were no substantial differences between the treatment arms.” Furthermore, about 70% of the participants achieved a BP below 140/90 mmHg and about 40% reached a BP below 130/80. In total, 2.6% of participants discontinued the study drug due to drug-related AEs.
“Dual combination hypertensive therapies were effective, well-tolerated, and safe in Indian patients with hypertension,” concluded Prof. Prabhakaran.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2024 Medicom Medical Publishers
